Establishment Labs (NASDAQ:ESTA) Upgraded by Wall Street Zen to “Hold” Rating

by · The Markets Daily

Wall Street Zen upgraded shares of Establishment Labs (NASDAQ:ESTA – Free Report) from a sell rating to a hold rating in a research report report published on Sunday morning.

A number of other research firms also recently issued reports on ESTA. Weiss Ratings reiterated a “sell (d-)” rating on shares of Establishment Labs in a report on Wednesday, October 8th. Mizuho lifted their price objective on shares of Establishment Labs from $58.00 to $70.00 and gave the company an “outperform” rating in a report on Wednesday, July 16th. Canaccord Genuity Group initiated coverage on shares of Establishment Labs in a report on Wednesday, August 20th. They issued a “buy” rating and a $60.00 price objective on the stock. Finally, Citigroup reiterated a “neutral” rating on shares of Establishment Labs in a report on Tuesday, October 7th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $56.50.

Check Out Our Latest Stock Report on Establishment Labs

Establishment Labs Stock Performance

Shares of ESTA stock opened at $47.26 on Friday. The company has a debt-to-equity ratio of 9.71, a quick ratio of 1.67 and a current ratio of 2.84. The company has a market capitalization of $1.37 billion, a P/E ratio of -15.50 and a beta of 0.85. The company’s 50 day moving average price is $40.10 and its two-hundred day moving average price is $38.20. Establishment Labs has a 52 week low of $26.56 and a 52 week high of $50.85.

Establishment Labs (NASDAQ:ESTA – Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.54) by ($0.03). Establishment Labs had a negative return on equity of 224.34% and a negative net margin of 49.89%.The company had revenue of $51.30 million for the quarter, compared to analyst estimates of $50.80 million. During the same quarter last year, the business posted ($0.62) earnings per share. The business’s quarterly revenue was up 16.1% on a year-over-year basis. Establishment Labs has set its FY 2025 guidance at EPS. On average, analysts expect that Establishment Labs will post -2.41 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Establishment Labs

A number of institutional investors have recently added to or reduced their stakes in ESTA. ANTIPODES PARTNERS Ltd acquired a new position in Establishment Labs during the first quarter worth $81,000. Osaic Holdings Inc. increased its holdings in Establishment Labs by 900.0% during the second quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock worth $85,000 after buying an additional 1,800 shares during the last quarter. CWM LLC increased its holdings in Establishment Labs by 45.9% during the second quarter. CWM LLC now owns 2,182 shares of the company’s stock worth $93,000 after buying an additional 686 shares during the last quarter. Brian Low Financial Group LLC acquired a new position in Establishment Labs during the third quarter worth $223,000. Finally, Patriot Financial Group Insurance Agency LLC increased its holdings in Establishment Labs by 5.2% during the second quarter. Patriot Financial Group Insurance Agency LLC now owns 6,025 shares of the company’s stock worth $257,000 after buying an additional 300 shares during the last quarter. 72.91% of the stock is currently owned by institutional investors and hedge funds.

About Establishment Labs

(Get Free Report)

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.

Featured Stories